

Inter Patent Application of

Atty Dkt. 555-56

C# M#

SCHREIBER

Group Art Unit: 1617


Serial No. 09/535,951

Examiner: Hui, S.

Filed: March 27, 2000

Date: December 17, 2003

Title: METHOD OF TREATING ATHEROSCLEROSIS



1617  
#

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.**

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 86.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$290.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

**Subtotal \$ 0.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 3 Information Disclosure Statement Filing Fee (\$180.00) \$ 180.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

**TOTAL FEE ENCLOSED \$ 180.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:tat

NIXON & VANDERHYE P.C.  
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SCHREIBER

Atty. Ref.: 555-56  
Confirmation No. 4293

Serial No. 09/535,951

Group: 1617

Filed: March 27, 2000

Examiner: Hui, S.

For: METHOD OF TREATING ATHEROSCLEROSIS

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

December 17, 2003

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☒ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each  
identified document and a translation or a concise explanation of  
each non-English language document (such as a Search Report) is  
enclosed herewith.

12/18/2003 CCHAU1 00000074 09535951

01 FC:1806

180. OP

796172


This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1<sup>st</sup> Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

SCHREIBER  
Serial No. 09/535,951  
December 17, 2003

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By:

  
Mary J. Wilson  
Reg. No. 32,955

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

555-56

09/535,951

APPLICANT

SCHREIBER

FILING DATE

GROUP

March 27, 2000

1617

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Barbieri and Ryan, "Direct effects of medroxyprogesterone acetate (MPA) and megestrol acetate (MGA) on rat testicular steroidogenesis", Acid Endocrinologica 94:419-425 (1980)
	Roubinian et al, "Androgenic Hormones Modulate Autoantibody Responses and Improve Survival in Murine Lupus", The Journal of Clinical Investigation 59:1066-1070 (1977)
	Lahita, "Sex Steroids and the Rheumatic Diseases", Arthritis and Rheumatism 28(2):121-126 (1985)
	Lahita et al, "Increased Oxidation of Testosterone in Systemic Lupus Erythematosus", Arthritis and Rheumatism 26(12):1517-1521 (1983)
	Schreiber et al, "Effect of Endogenous and Synthetic Sex Steroids on the Clearance of Antibody-Coated Cells", The Journal of Immunology 141(9):2959-2966 (1988)
	Pritchard and MacDonald, "The Placental Hormones and Their Precursors", Williams Obstetrics, Sixteenth Edition, Pub. Appelton-Century-Crofts, New York, Chapter 7, pgs. 147-168
	Haynes, Jr. and Lerner, "Adrenocorticotrophic Hormone; Adrenocortical Steroids and Their Synthetic Analogs; Inhibitors of Adrenocortical Steroid Biosynthesis", "The Pharmacological Basis of Therapeutics, Fifth Edition, Goodman and Gilman, eds., Macmillian Publishing Co., Inc., Chapter 70, pgs. 1472-1506 (1976)
	Siiteri et al, "Sex Steroids and the Immune System - I. Sex Difference in Autoimmune Disease in NZB/NZW Hybrid Mice", Journal of Steroid Biochemistry 12:425-432 (1980)
	Jungers et al, "Hormonal Modulation in Systemic Lupus Erythematosus", Arthritis and Rheumatism 28(11):1243-1250 (1985)
	Duncan, M.R. and Duncan, G.R., "An In Vivo Study of the Action of Antigluco corticoids on Thymus Weight Ratio, Antibody Titre and the Adrenal-Pituitary-Hypothalamus Axis", Journal of Steroidal Biochemistry 10:245-259 (1979)
	Siiteri and Stites, "Immunologic and Endocrine Interrelationships in Pregnancy", Biology of Reproduction 26:1-14 (1982)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

555-56

09/535,951

APPLICANT

SCHREIBER

FILING DATE

GROUP

March 27, 2000

1617

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Barbieri and Ryan, "Direct effects of medroxyprogesterone acetate (MPA) and megestrol acetate (MGA) on rat testicular steroidogenesis", Acid Endocrinologica 94:419-425 (1980)
	Roubinian et al, "Androgenic Hormones Modulate Autoantibody Responses and Improve Survival in Murine Lupus", The Journal of Clinical Investigation 59:1066-1070 (1977)
	Lahita, "Sex Steroids and the Rheumatic Diseases", Arthritis and Rheumatism 28(2):121-126 (1985)
	Lahita et al, "Increased Oxidation of Testosterone in Systemic Lupus Erythematosus", Arthritis and Rheumatism 26(12):1517-1521 (1983)
	Schreiber et al, "Effect of Endogenous and Synthetic Sex Steroids on the Clearance of Antibody-Coated Cells", The Journal of Immunology 141(9):2959-2966 (1988)
	Pritchard and MacDonald, "The Placental Hormones and Their Precursors", Williams Obstetrics, Sixteenth Edition, Pub. Appelton-Century-Crofts, New York, Chapter 7, pgs. 147-168
	Haynes, Jr. and Lerner, "Adrenocorticotrophic Hormone; Adrenocortical Steroids and Their Synthetic Analogs; Inhibitors of Adrenocortical Steroid Biosynthesis", "The Pharmacological Basis of Therapeutics, Fifth Edition, Goodman and Gilman, eds., Macmillian Publishing Co., Inc., Chapter 70, pgs. 1472-1506 (1976)
	Siiteri et al, "Sex Steroids and the Immune System - I. Sex Difference in Autoimmune Disease in NZB/NZW Hybrid Mice", Journal of Steroid Biochemistry 12:425-432 (1980)
	Jungers et al, "Hormonal Modulation in Systemic Lupus Erythematosus", Arthritis and Rheumatism 28(11):1243-1250 (1985)
	Duncan, M.R. and Duncan, G.R., "An In Vivo Study of the Action of Antigluco corticoids on Thymus Weight Ratio, Antibody Titre and the Adrenal-Pituitary-Hypothalamus Axis", Journal of Steroidal Biochemistry 10:245-259 (1979)
	Siiteri and Stites, "Immunologic and Endocrine Interrelationships in Pregnancy", Biology of Reproduction 26:1-14 (1982)

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.